Yonsa, New Formulation of Abiraterone Acetate, Approved for Advanced Castration-resistant Prostate Cancer

Yonsa, New Formulation of Abiraterone Acetate, Approved for Advanced Castration-resistant Prostate Cancer
Yonsa was recently approved by the U.S. Food and Drug Administration, in combination with methylprednisolone, for the treatment of metastatic castration-resistant prostate cancer. The announcement was made by Sun Pharma and Churchill Pharmaceuticals. Yonsa is a new formulation of abiraterone acetate, an already approved hormone therapy for men with advanced, castration-resistant prostate cancer, sold under the brand name

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *